

Resource Summary Report

Generated by [nidm-terms](#) on Jul 28, 2026

Creighton University Auditory and Vestibular Technology Core Facility

RRID:SCR_023866

Type: Tool

Proper Citation

Creighton University Auditory and Vestibular Technology Core Facility
(RRID:SCR_023866)

Resource Information

URL: <https://www.creighton.edu/medicine/departments/biomedical-sciences/translational-hearing-center/technology>

Proper Citation: Creighton University Auditory and Vestibular Technology Core Facility
(RRID:SCR_023866)

Description: Core was established to provide infrastructure to support Research Project Leaders and principle investigators associated with the Dr. Richard J. Bellucci Translational Hearing Center to conduct auditory and vestibular research across the full range of experimental model systems, from single molecule analysis to whole organism models. We also offer access to our services and instruments to outside users.

Abbreviations: AVT

Synonyms: CU-AVT Core Imaging Facility, Creighton University CU-AVT Core Imaging Facility

Resource Type: access service resource, core facility, service resource

Keywords: USEDit, ABRF, auditory and vestibular research, experimental model systems, single molecule analysis, whole organism models,

Availability: Open

Resource Name: Creighton University Auditory and Vestibular Technology Core Facility

Resource ID: SCR_023866

Alternate IDs: ABRF_1810

Alternate URLs: <https://coremarketplace.org/?FacilityID=1810&citation=1>

Record Creation Time: 20230722T050213+0000

Record Last Update: 20260728T043703+0000

Ratings and Alerts

No rating or validation information has been found for Creighton University Auditory and Vestibular Technology Core Facility.

No alerts have been found for Creighton University Auditory and Vestibular Technology Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Nayak MK, et al. (2026) Targeting the melanocytes of the inner ear: A comparison of different CreER lines. *Developmental biology*, 530, 224.

Manickam V, et al. (2025) Paving the way for better ototoxicity assessments in cisplatin therapy using more reliable animal models. *Frontiers in cellular neuroscience*, 19, 1552051.

Renauld JM, et al. (2025) Lmx1a is essential for marginal cell differentiation and stria vascularis formation. *Frontiers in cell and developmental biology*, 13, 1537505.

Rocha-Sanchez SM, et al. (2025) Design and Synthesis of New Quinoxaline Analogs to Regenerate Sensory Auditory Hair Cells. *Cells*, 14(24).

Palmer VL, et al. (2025) RACK1 is required for normal B cell development and signaling but not RAG1 degradation. *Journal of immunology (Baltimore, Md. : 1950)*.

Sailor-Longsworth EJ, et al. (2024) Oseltamivir (Tamiflu), a commonly prescribed antiviral drug, mitigates hearing loss in mice. *Clinical and translational medicine*, 14(8), e1803.

Sailor-Longsworth E, et al. (2024) Oseltamivir (Tamiflu), a Commonly Prescribed Antiviral Drug, Mitigates Hearing Loss in Mice. *bioRxiv : the preprint server for biology*.

Lutze RD, et al. (2024) FDA-Approved MEK1/2 Inhibitor, Trametinib, Protects Mice from Cisplatin and Noise-Induced Hearing Loss. *bioRxiv : the preprint server for biology*.

Ingersoll MA, et al. (2024) KSR1 Knockout Mouse Model Demonstrates MAPK Pathway's Key Role in Cisplatin- and Noise-induced Hearing Loss. *The Journal of neuroscience : the official journal of the Society for Neuroscience*, 44(18).

Lutze RD, et al. (2024) ERK1/2 Inhibition via the Oral Administration of Tizaterkib Alleviates Noise-Induced Hearing Loss While Tempering down the Immune Response. International journal of molecular sciences, 25(12).

Lutze RD, et al. (2024) Trametinib, a MEK1/2 Inhibitor, Protects Mice from Cisplatin- and Noise-Induced Hearing Loss. Pharmaceuticals (Basel, Switzerland), 17(6).

Ingersoll MA, et al. (2023) KSR1 knockout mouse model demonstrates MAPK pathway's key role in cisplatin- and noise-induced hearing loss. bioRxiv : the preprint server for biology.

Lutze RD, et al. (2023) ERK1/2 Inhibition Alleviates Noise-Induced Hearing Loss While Tempering Down the Immune Response. bioRxiv : the preprint server for biology.

Ingersoll MA, et al. (2023) Dabrafenib protects from cisplatin-induced hearing loss in a clinically relevant mouse model. JCI insight, 8(24).